Progress of Matrix metalloproteinases and their Inhibitors in Cardiovascular disease
-
摘要: 基质金属蛋白酶(MMPs)及其抑制剂(TIMPs)在心肌细胞的损伤、心肌重构中有着重要的影响,因其发生发展过程复杂,主要机理目前还不完全明确,但众多研究表明,MMPs和TIMPs的动态平衡在心肌损伤中起着至关重要的作用,甚至可以为心肌梗死的早期检测和及早治疗而开发出一种新型的检测试剂,可以有效提高心血管疾病的早期诊断,对后续的治疗起到准确、科学的指导作用。下面就基质金属蛋白酶及其抑制剂在心血管疾病方面近几年的研究结果进行综述。
-
关键词:
- 基质金属蛋白酶及其抑制剂 /
- 心肌重构 /
- 动态平衡
Abstract: Matrix metalloproteinases and their inhibitors have a significant impact on Myocardial injury and remodeling in cardiac myocytes.Because of the complex development process,the main mechanism is unentire clear. A few studies have shown that dynamic equilibrium between MMPs and TIMPs played a vital role in myocardial injury, and it could develop a new detection reagents for early detection and early treatment of myocardial infarction. It not only can effectively improve the early diagnosis of cardiovascular disease, but also plays accurate scientific guidance subsequent treatment. Now it will be summarized that the progress of Matrix metalloproteinases and their inhibitors in Cardiovascular disease in recent years . -
[1] Gray R. Matrix metalloproteinases and their multipile roles in nrurodege-nerative disease[J]. Lancet Neurol, 2009, 8(2): 205-16. doi: 10.1016/S1474-4422(09)70016-X [2] Dolllery CM, Jean R. Matrix metalloproteinases and cardiovascular disease[J]. Circ Res, 1995, 77(8): 863-8. [3] Armiento JD. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction[J]. Trends Cardiovasc Med, 2002, 12(3): 97-101. doi: 10.1016/S1050-1738(01)00160-8 [4] Gomez D, Alonso DF, Yoshiji H, et al. Tissue inhibitors of metalloproteinases:structure regulation and biological functions[J]. Eur J Cell Biol, 1997, 74(2): 111-22. [5] Roten L, Nemoto S, Simsic J, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice[J]. J Mol Cell Cardiol, 2000, 32(1): 109-20. doi: 10.1006/jmcc.1999.1052 [6] KaiH, IkedaH, Yasukawa H, et al. l peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patientswith acute coronary syndromes[J]. Am CollCardio, (32): 368-72. [7] Yamazaki T, Lee JD, Shimizu H, et al. l circulating matrix metalloproteinase-2 is elevated in patientswith congestive heart failure[J]. Eur JHeartFai, 2004, (6): 41-5. [8] Nishikawa N, Yamamoto K, Sakata Y, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation[J]. Cardiovasc Res, 2003, 57(3): 766-74. doi: 10.1016/S0008-6363(02)00792-7 [9] Li MJ, Huang CX, Okello E, et al. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology[J]. Can J Cardiol, 2009, 25(9): 523-6. doi: 10.1016/S0828-282X(09)70138-2 [10] Frank LD, Simona B, Gani B, et al. l plasma matrix metalloproteinase-9 better predicts outcome than n-terminal protype-B natriuretic peptide in patientswith systolic heart failure and a high prevalence of coronary artery disease[J]. Biomedic Pharmacother, 2010, 64(4): 339-42. [11] Roten L, Nemoto S, Simsic J, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice[J]. J Mol Cell Cardiol, 2000, 32(1): 109-20. doi: 10.1006/jmcc.1999.1052 [12] Heymans S, Luttun A, Nuyens DA. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure[J]. Nat Med, 1999, 5(8): 1135-42. [13] Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction[J]. J Clin Invest, 2000, 106(1): 55-62. doi: 10.1172/JCI8768 [14] Maisch B, Alter P, Karatolius K, et al. Theheart in cases of viralbacterial and parasitic infections[J]. Internist (Berl), 2007, 48 (3): 255-67. doi: 10.1007/s00108-006-1775-8 [15] Jeserich M, Konstantinides S, Pavlik GA, et al. Non-invasive imaging in the diagnosis of acute viral myocarditis[J]. Clin Res Cardiol, 2009, 98(12): 753-63. doi: 10.1007/s00392-009-0069-2 [16] 蔡小芳, 麦根荣, 徐之良. 小儿扩张型心肌病与病毒性心肌炎的临床研究[J]. 中国当代儿科杂志, 2004, 6(4): 325-7. http://www.cnki.com.cn/Article/CJFDTOTAL-DDKZ200404026.htm [17] Heymans S, Pauschinger M, De Palma AA, et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis[J]. Circulation, 2006, 114(6): 565-73. doi: 10.1161/CIRCULATIONAHA.105.591032 [18] Nelissen I, Martens E. Van den Steen PE, Proost P, Ronsse I Opdenakker G Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy[J]. Brain, 2003, 126(Pt 6): 1371-81. [19] Li J, Schwimmbeck PL, Tschope C, et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction[J]. Cardiovasc Res, 2002, 56(2): 235-47. doi: 10.1016/S0008-6363(02)00546-1 [20] Schnbeck U. Mach F,libby P.Generation of biologically active IL-1 beta by matrix metalloproteinases:a novel caspase-1 Independent pathway of IL-1 beta processing[J]. J Immunol, 1998, 161(7): 3340-6. [21] Meng XH, Wang Y, Zhuang JX, et al. Dynamic changes in myocardial matrix metalloproteinase activity in mice with viral myocarditis[J]. Chin Med J (Engl), 2004, 117(8): 1195-9. [22] Graham HK, Horn M, Trafford AW. Extracellular matrix profiles in the progression to heart failure[J]. Acta Physiologica, 2008, 194(1): 3-21. doi: 10.1111/aps.2008.194.issue-1 [23] Li YY. MC tiernan C F,feldman a M.interplay of matrix metalloproteinase, tissue inhibitors of metalloproteinase and their regulators in cardiac matrix remodeling[J]. Cardivasc Res, 2000, 46 (2): 214-24. doi: 10.1016/S0008-6363(00)00003-1 [24] Levick SP, Browerg L. Regulation ofmatrix metalloproteinase is at the heart of myocardial remodeling[J]. Am J Physiol Heart Circ Physiol, 2008, 295(4): H1375-6. doi: 10.1152/ajpheart.907.2008 [25] Zavadzkas JA, Plyler RA, Bouges S, et al. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causesmyocardial remodeling and dysfunction in aging mice[J]. Am J Physiol Heart Circ Physiol, 2008, 295(4): H1394-402. doi: 10.1152/ajpheart.00346.2008 [26] 赵元, 周新民, 廖晓波, 等. 风湿性心脏病致心力衰竭患者心肌组织中基质金属蛋白酶-1, 9及其相关因子TIMP-4和EMMPRIN的表达及意义[J]. 中南大学学报: 医学版, 2009, 34(8): 790-5. http://www.cnki.com.cn/Article/CJFDTOTAL-HNYD200908021.htm [27] RouisM. Matrix metalloproteinases:a potential therapeutic target in atherosclerosis[J]. Curr Drug Targets Cardiovasc Haematol Disord, 2005, 5(9): 541-8. [28] KaiH, Ikeda H,Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes[J].Am Coll Cardio, 1998, 32: 368-72. doi: 10.1016/S0735-1097(98)00250-2 [29] Webb CS, Bonnema DD, Ahmed SH, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction:relation to left ventricular remodeling[J]. Circulation, 2006, 114(10): 1020-7. doi: 10.1161/CIRCULATIONAHA.105.600353
点击查看大图
计量
- 文章访问数: 520
- HTML全文浏览量: 198
- PDF下载量: 2
- 被引次数: 0